VANCOUVER, BC — February 17, 2026 — Leads & Copy — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2), a FemTech medical device company, announced it is scaling manufacturing to produce 250 clinical-grade prototypes of its ZC-001 therapeutic device, adhering to ISO 13485-certified quality standards.
The production milestone supports further preclinical testing under Good Laboratory Practice (GLP) standards. The company remains on track to begin a clinical study with at least 100 women in Q4 2026 to evaluate efficacy, following prior laboratory testing that demonstrated 99.999% fungal eradication under controlled conditions. Completion of the 250 units is expected within 90 days.
According to Eli Ben-Haroosh, Chief Executive Officer of Zero Candida, scaling production will help the company transition from laboratory validation to human studies more efficiently. Ben-Haroosh added that this demonstrates their commitment to medical-grade excellence. He also stated that he looks forward to sharing updates as the company advances on its 2026 roadmap to bring solutions to women worldwide living with recurrent VVC.
ZC-001 is a SMART, AI-enabled therapeutic device that integrates precision blue light therapy, targeted drug delivery, and wireless diagnostics for personalized at-home treatment of Vulvovaginal Candidiasis (VVC). The device is designed to improve outcomes in recurrent and drug-resistant infections, reducing the need for repeated in-clinic visits. The underlying technology may support future applications across other areas of women’s health.
Zero Candida Technologies, Inc. is a publicly traded FemTech company developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light to treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. The company said that approximately 75% of women worldwide are affected by this condition, and recurrent cases are increasingly resistant to existing drug treatments. The VVC treatment market is projected to exceed US $2B by 2030. Zero Candida combines hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century.
Source: Zero Candida Technologies, Inc.
